CD274 and lymphoma: Despite a strong rationale for the combination of ibrutinib with PD‐1/PD‐L1‐targeted therapy and preclinical evidence in murine lymphoma models for synergistic antitumor activity with ibrutinib plus durvalumab,3 the highest responses seen in our study during dose confirmation (90%; Arm B, durvalumab 1500 mg + ibrutinib 420 mg) and dose finding (75%; Arm B, durvalumab 1500 mg + ibrutinib 560 mg) were similar to or lower than previous reports of responses to ibrutinib monotherapy among patients with relapsed/refractory CLL.30